Visium Asset Management’s Pacific Biosciences PACB Stock Holding History

Visium Asset Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-39,659	Closed	-$279K	–	146
2016 Q2	$279K	Buy	+39,659	New	+$362K	0.02%	297
2015 Q3	–	Sell	-10,300	Closed	-$59K	–	1115
2015 Q2	$59K	Buy	+10,300	New	+$59.6K	﹤0.01%	1073
2013 Q4	–	Sell	-20,000	Closed	-$111K	–	952
2013 Q3	$111K	Sell	20,000 -994,000	-98%	-$3.45M	﹤0.01%	731
2013 Q2	$2.56M	Buy	+1,014,000	New	+$2.52M	0.06%	201

Other funds holding PACB

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Visium Asset Management's PACB Position: Q3 2016 in Review

Visium Asset Management sold out of Pacific Biosciences (PACB) in Q3 2016, closing a stake of 39,659 shares — an estimated $279K sold.

Visium Asset Management first reported a position in PACB in Q2 2013 and held it in 4 quarters. The position peaked at $2.56M in Q2 2013. 128 funds tracked by Wall St. Rank hold PACB as of Q3 2016.

Visium Asset Management reported no remaining Pacific Biosciences position as of Q3 2016 after selling out during the quarter.
Visium Asset Management sold 39,659 Pacific Biosciences shares in Q3 2016, an estimated $279K.
Visium Asset Management first reported a position in Pacific Biosciences in Q2 2013 and held it in 4 quarters.
Visium Asset Management's Pacific Biosciences position peaked at $2.56M in Q2 2013.
128 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2016.

Based on Visium Asset Management's 13F filing for Q3 2016.